A 4/8 Subtype α-Conotoxin Vt1.27 Inhibits N-Type Calcium Channels With Potent Anti-Allodynic Effect

Area of Science:

• Marine biotechnology
• Neuropharmacology
• Pain research

Background:

• Alpha-conotoxins are peptides from cone snails known to interact with nicotinic acetylcholine receptors (nAChRs).
• Neuropathic pain, a debilitating condition, requires novel therapeutic agents.
• Understanding conotoxin targets is crucial for developing new analgesics.

Purpose of the Study:

• To identify and characterize a novel alpha-conotoxin from Conus vitulinus.
• To investigate the molecular targets and analgesic potential of the new conotoxin, Vt1.27.
• To explore Vt1.27 as a therapeutic candidate for neuropathic pain.

Main Methods:

• Rapid amplification of complementary DNA ends (RACE) for conotoxin identification.
• Peptide synthesis, structural characterization, and in vitro channel assays (nAChR, CaV2.2).
• Alanine scanning mutagenesis and molecular docking studies.
• In vivo assessment of anti-allodynic effects in rat neuropathic pain models (PNI, CCI).

Main Results:

• A novel 4/8 subtype alpha-conotoxin, Vt1.27, was identified and synthesized.
• Vt1.27 inhibited rat alpha3beta2 nAChR (IC50 = 1160 nM) and potently inhibited N-type CaV2.2 calcium channels (IC50 = 398 nM).
• Key residues (Phe5, Pro9, Ile10, Ser13) were identified as crucial for Vt1.27 activity.
• Vt1.27 demonstrated significant anti-allodynic effects in rat sciatic nerve injury models, outperforming Vc1.1 in CCI models.

Conclusions:

• Vt1.27 represents a novel conotoxin with dual activity, targeting both nAChRs and CaV2.2 channels.
• The inhibition of CaV2.2 channels by Vt1.27 occurs in the transmembrane region, distinct from omega-conotoxins.
• Vt1.27 shows significant therapeutic potential as an anti-allodynic agent for neuropathic pain treatment.